P4, N=50, Recruiting, Erasmus Medical Center

P=N/A, N=66, Recruiting, Northern Theater Command General Hospital of the Chinese People's Liberation Army; Northern Theater Command General Hospital of the Chinese People's L

P4, N=134, Not yet recruiting, Inner Mongolia Medical University Affiliated Hospital; Inner Mongolia Medical University Affiliated Hospital

P2, N=51, Completed, Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting --> Completed

P1, N=32, Completed, Cairo University

P4, N=60, Not yet recruiting, Baylor College of Medicine

Here, a novel combination therapy consisting of the calcineurin inhibitor cyclosporine A (CsA) and the flavone-naphthalimide-polyamine derivative 6c was identified...Finally, combination of CsA and 6c suppressed tumor growth and pulmonary metastasis in vivo. Overall, our study suggests a novel synergistic treatment combination with a comprehensive mechanistic exploration, demonstrating that it is a promising strategy for HCC treatment via targeting RIG-I-like receptor signaling.

P3, N=477, Terminated, Famy Life Sciences, a Viatris Company | Active, not recruiting --> Terminated; Sponsor Decision

This drug-induced partial immunosuppression protocol effectively creates a reproducible state of transient immunodeficiency in outbred mice, suitable for various human tumor xenograft models. It represents a cost-effective and flexible alternative to genetic models, with the distinct advantage of preserving a residual immune microenvironment, making it particularly valuable for preclinical studies that require a partially intact host immune system.

P1, N=50, Not yet recruiting, Stanford University

The use of ruxolitinib and cyclosporin A has been shown to be beneficial for such patients. And the use of ruxolitinib decreases the dosage of cyclosporin A, indicating that ruxolitinib may have a therapeutic effect on PRCA.

A 59-year-old woman with ER/PR (90% strong+), HER2-negative metastatic breast cancer developed pruritic hypopigmented patches on her forearms 16 months after initiating ribociclib/letrozole...Topical 0.1% mometasone cream and 0.1% tacrolimus ointment were initiated, with stabilization of existing lesions and no new depigmentation at 2-month follow-up...Combined with prior reports, it suggests a link between ribociclib and vitiligo. Further clinical observations and studies are needed to confirm causality, and pre-use risk explanations to patients are advisable.